SEC filing · 20-F

Regencell Bioscience Holdings Ltd: Annual report (foreign issuer)

Regencell Bioscience reported a widening net loss of $11,701,941 for fiscal year 2026 as operating costs rose sharply and the company generated zero revenue.

Filed October 7, 2026 · period ended June 30, 2026

Negative for the company

What the numbers say

Diluted EPS -$2.37 versus -$0.72; operating cash flow -$7.7M (a year earlier -$3.1M); cash rose by $11.8M to $14.2M.

Compared with the same period a year earlier, from the figures Regencell Bioscience Holdings Ltd reported to the SEC.

What happened

The company did not generate any revenue as its TCM formula products remain in development.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Regencell Bioscience Holdings Ltd

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.